Magenta Therapeutics Competitors, Revenue and Alternatives
Estimated Revenue & Financials
- Magenta Therapeutics's estimated annual revenue is currently $8.5M per year.
- Magenta Therapeutics received $52.0M in venture funding in April 2018.
- Magenta Therapeutics's estimated revenue per employee is $105,247
- Magenta Therapeutics's total funding is $219.7M.
- Magenta Therapeutics has 81 Employees.
- Magenta Therapeutics grew their employee count by -4% last year.
- Magenta Therapeutics currently has 10 job openings.
|Competitor Name||Revenue||Number of Employees||Employee Growth||Total Funding|
|Cell Signaling ...||$89.4M||577||N/A||N/A|
What Is Magenta Therapeutics?
Magenta Therapeutics is a biotechnology company harnessing the power of stem cell science to revolutionize stem cell transplantation for patients with immune- and blood-based diseases. By creating a platform focused on key areas of transplant medicine, Magenta Therapeutics is pioneering an integrated, but modular approach to stem cell therapies that reboot the blood and immune systems to create patient benefit. Founded by internationally recognized leaders in stem cell transplant medicine, Magenta Therapeutics was launched in 2016 by Third Rock Ventures and Atlas Venture and is headquartered in Cambridge, Mass. For more information, please visit www.magentatx.com.keywords:N/A
Number of Employees
Employee Growth %
|William Neeley||Head Of Intellectual Property||Email Available|
|Ganapathy Sarma||Director||Email Available|
|Zoran Zdraveski||Chief Legal Officer and Corporate Secretary||Email Available|
|Christopher Wilson||Manager, CMC Process Analytics||Email Available|
|Daniel Park||Director, Legal Affairs||Email Available|
|Jan Pinkas||Senior Vice President||Email Available|
|Greg Dwyer||Senior Director, Business Development||Email Available|
|Haley Howell||Associate Director, Clinical Operations||Email Available|
|Veit Schmelmer||Vice President, Program Lead||Email Available|
|Jason Gardner||CEO, President and Cofounder||Email Available|
Magenta Therapeutics News
The FCF Growth of Magenta Therapeutics, Inc. (NasdaqGM:MGTA) is . Free cash flow (FCF) is the cash produced by the company minus ...
Alps Advisors Inc. purchased a new stake in shares of Magenta Therapeutics Inc (NASDAQ:MGTA) during the 2nd quarter, according to its most ...
35 days have passed by since the last earnings report for Magenta Therapeutics, Inc. (NASDAQ:MGTA) and the new quarterly results look set ...
Magenta Therapeutics Funding
|2016-11-17||$48.5M||A||Third Rock Ventures, LLC||Article|
Magenta Therapeutics Executive Hires
|2017-10-27||Charlotte McDonagh||VP Biotherapeutics||Article|
|2018-02-22||John Davis||Chief Medical Officer||Article|
|2018-03-09||Christina Isacson||Chief Business Officer||Article|